Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
API
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1263-w-94
2. 1263w94
3. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosylbenzimidazole
4. Benzimidavir
5. Bw 1263w94
6. Bw-1263w94
7. Gw 1263
8. Gw 257406x
9. Gw-1263
10. Gw-257406x
11. Gw257406x
1. 176161-24-3
2. Benzimidavir
3. 1263w94
4. Livtencity
5. (2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
6. Camvia
7. Bw-1263w94
8. Gw-257406x
9. Gw-1263
10. Ptb4x93he1
11. (2s,3s,4r,5s)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
12. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1h-benzimidazole
13. 1263-w-94
14. Gw257406x
15. G1263
16. Maribavir [usan]
17. Unii-ptb4x93he1
18. Maribavir [usan:inn:ban]
19. Camvia(tm)
20. Camvia (tn)
21. Bw 1263w94
22. Maribavir [inn]
23. Maribavir (usan/inn)
24. Maribavir [who-dd]
25. Schembl791309
26. Chembl515408
27. Gtpl12049
28. Dtxsid60170091
29. Zinc3824412
30. Bw1263w94
31. 5,6-dichloro-2-(isopropylamino)-1-(beta-l-ribofuranosyl)-1h-benzimidazole
32. Akos015962194
33. Db06234
34. Gw 1263
35. Gw 257406x
36. 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine
37. Ncgc00378559-03
38. Ac-22286
39. As-49903
40. Hy-16305
41. Vp-41263
42. D04859
43. O10059
44. Q6762512
45. Maribavir (1263w94, Benzimidazole D-ribose Derivative)
46. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosylbenzimidazole
47. 5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)benzimidazole
48. 5,6-dichloro-2-isopropylamino-1-(beta-l-ribofuranosyl)-1h-benzimidazole
49. 1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-
50. 1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-
51. 5,6-dichloro-2-(isopropylamino)-1-.beta.-l-ribofuranosylbenzimidazole
52. 5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-1h-benzimidazol-2-amine
53. (2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
54. (2s,3s,4r,5s)-2-[5,6-dichloro-2-(isopropylamino)benzimidazol-1-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
Molecular Weight | 376.2 g/mol |
---|---|
Molecular Formula | C15H19Cl2N3O4 |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 375.0752615 g/mol |
Monoisotopic Mass | 375.0752615 g/mol |
Topological Polar Surface Area | 99.8 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 447 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Maribavir is indicated for the treatment of adult and pediatric patients (weighing >35kg and at least 12 years old) with post-transplant cytomegalovirus (CMV) infection which is refractory to standard treatment with [ganciclovir], [valganciclovir], [cidofovir], or [foscarnet].
Cytomegaloviral disease
Treatment of cytomegalovirus (CMV) infection
Maribavir exerts its antiviral efficacy via an alternative target as compared to traditional CMV antivirals and is thus useful in the treatment of CMV infections that have proven resistant to standard therapy. Maribavir should not be used concomitantly with ganciclovir or valganciclovir, as these molecules both require activation via CMV pUL97 in order to exert their antiviral effect. Taking them alongside maribavir - an inhibitor of this same kinase - will therefore significantly reduce their antiviral activity.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AX - Other antivirals
J05AX10 - Maribavir
Absorption
Population pharmacokinetic modeling in patients receiving maribavir 400mg twice daily showed an AUC0-tau and Cmax of 128 g.h/mL and 17.2 g/mL, respectively. It has a median Tmax of one to three hours.
Route of Elimination
Maribavir is eliminated primarily via hepatic metabolism. Following the oral administration of radiolabeled maribavir, 61% of the dose was excreted in the urine (<2% as unchanged drug) and 14% was excreted in the feces (5.7% as unchanged drug).
Volume of Distribution
The mean apparent steady-state volume of distribution for maribavir was 27.3 L.
Clearance
In post-transplant patients, the mean oral clearance of maribavir was 2.85 L/h.
Maribavir is extensively metabolized following oral administration, primarily by CYP3A4 and, to a lesser extent, by CYP1A2. Its major circulating metabolite is VP 44469, an inactive N-dealkylated metabolite.
In post-transplant patients, the mean half-life of elimination was 4.32 hours.
Human cytomegalovirus (CMV) is a herpesvirus commonly causing infection in patients following stem cell or organ transplants. As with other herpesviruses, CMV tends to persist in the host and become reactivated under immunosuppressive conditions - patients requiring multiple immunosuppressive medications to combat transplant rejection are thus at a much higher risk of developing serious CMV infections. Maribavir belongs to a class of anti-cytomegalovirus antivirals called benzimidazole ribosides. It competitively inhibits the human CMV pUL97 viral protein kinase, which results in viable but severely defective viruses upon replication, although the reasons for this remain poorly defined. In addition, maribavir also inhibits viral release from the nucleus to the cytoplasm by inhibiting pUL97-dependent phosphorylation of the nuclear lamina component lamin A/C, although the extent to which this activity contributes to its antiviral efficacy is unclear.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Patents & EXCLUSIVITIES
Patent Expiration Date : 2032-01-04
US Patent Number : 11684632
Drug Substance Claim :
Drug Product Claim :
Application Number : 215596
Patent Use Code : U-3650
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-01-04
Exclusivity Code : NCE
Exclusivity Expiration Date : 2026-11-23
Application Number : 215596
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-388
Exclusivity Expiration Date : 2028-11-23
Application Number : 215596
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
A Maribavir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maribavir, including repackagers and relabelers. The FDA regulates Maribavir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maribavir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Maribavir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Maribavir supplier is an individual or a company that provides Maribavir active pharmaceutical ingredient (API) or Maribavir finished formulations upon request. The Maribavir suppliers may include Maribavir API manufacturers, exporters, distributors and traders.
click here to find a list of Maribavir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Maribavir Drug Master File in Korea (Maribavir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Maribavir. The MFDS reviews the Maribavir KDMF as part of the drug registration process and uses the information provided in the Maribavir KDMF to evaluate the safety and efficacy of the drug.
After submitting a Maribavir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Maribavir API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Maribavir suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maribavir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Maribavir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Maribavir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Maribavir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maribavir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Maribavir suppliers with NDC on PharmaCompass.
Maribavir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Maribavir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maribavir GMP manufacturer or Maribavir GMP API supplier for your needs.
A Maribavir CoA (Certificate of Analysis) is a formal document that attests to Maribavir's compliance with Maribavir specifications and serves as a tool for batch-level quality control.
Maribavir CoA mostly includes findings from lab analyses of a specific batch. For each Maribavir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Maribavir may be tested according to a variety of international standards, such as European Pharmacopoeia (Maribavir EP), Maribavir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maribavir USP).
LOOKING FOR A SUPPLIER?